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Summary 
Transthyretin (TTR) is a binding protein for the thyroid hormone thyroxine (T4), 
retinol and β-amyloid peptide. TTR aids the transfer of T4 from the blood to the 
cerebrospinal fluid (CSF), but also prevents T4 loss from the blood-CSF barrier. It is, 
however, unclear whether TTR affects the clearance of β-amyloid from the CSF. This 
study aimed to investigate roles of TTR in β-amyloid and T4 efflux from the CSF. 
Eight-week-old 129sv male mice were anaesthetized and their lateral ventricles were 
cannulated. Mice were infused with artificial CSF containing 125I-T4 / 3H-mannitol, or 
125I-Aβ40 / 3H-inulin, in the presence or absence of TTR. Mice were decapitated at 2, 
4, 8, 16, 24 minutes after injection. The whole brain was then removed and divided 
into different regions. The radioactivities in the brain were determined by liquid 
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scintillation counting. At baseline, the net uptake of 125I-T4 into the brain was 
significantly higher than that of 125I-Aβ40, and the half time for efflux was shorter 
(125I-T4, 5.16; 3H-mannitol, 7.44; 125I-Aβ40, 8.34; 3H-inulin, 10.78 minutess). The 
presence of TTR increased the half time for efflux of 125I-T4 efflux, and caused a 
noticeable increase in the uptake of 125I-T4 and 125I-Aβ40 in the choroid plexus, whilst 
uptakes of 3H-mannitol and 3H-inulin remained similar to control experiments. This 
study indicates that thyroxine and amyloid peptide effuse from the CSF using 
different transporters. TTR binds to thyroxine and amyloid peptide to prevent the loss 
of thyroxine from the brain and redistribute amyloid peptide to the choroid plexus.  
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1 INTRODUCTION 
 
Transthyretin (TTR), a highly conserved tetrameric protein of 55 kDa, is synthesized 
mainly in the liver and is also present in the choroid plexus (CP) and retina and in the 
cytoplasm of ependymal cells of brain ventricles.1 The CP contains 10 times more 
TTR mRNA in per gram of tissue than liver and secretes TTR at rate 13 times greater 
than liver.2 TTR production accounts for at least 20% of all protein synthesised by the 
CPs in the rat, and contributes approximately 50% of all secreted proteins into the 
cerebrospinal fluid (CSF).3,4 About 6% of total protein in CSF is TTR (~15 µg 
TTR mL–1 of CSF), which binds 80% of T4 in the CSF.5  
The secretion of TTR by the CP into CSF has been suggested to play a key 
role in the transfer of T4 from the blood to the CSF, as a unidirectional secretion of 
TTR to the CSF may drive thyroxin hormones (TH) across the blood-CSF barrier 
(BCB).6 In humans, TTR transports about 15% of plasma T4, and the rest of T4 are 
carried with other TH distributing proteins, e.g. thyroxine binding proteins (TBG), 
albumin.7 In TTR knockout (KO) mice, TTR absence does not impair TH tissue 
contents, despite the low circulating levels of total T4.8,9 These observations are in 
agreement with the free hormone hypothesis, that the hormone biological activity 
depends only on its free plasma concentration.10 In the CSF, TTR is a major T4 
carrier.5 It was reported that T4 distribution from the CSF into the brain is TTR-
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dependent and occurs via receptor-mediated endocytosis.11,12 The TTR-T4 interaction 
poses a preferential relevance in the brain than in the peripheral circulation, given 
there are two other T4 transporter proteins besides TTR being present in plasma with 
TBG having the highest affinity for T4, whereas TTR is the major carrier for T4 in the 
CSF. 
Besides being the carrier of T4 and retinol, TTR has been suggested to bind β-
amyloid peptide (Aβ) essentially protecting the brain from neurotoxic accumulations 
called amyloid plaques, a hallmark of Alzheimer’s disease (AD).13–16 TTR binds to 
both Aβ monomers and oligomers, but preferentially binds to the latter.17 TTR 
suppressed Aβ aggregation in vitro via an interaction between the thyroxine binding 
pocket of the TTR and Aβ residues 18–21,14 and prevents its toxicity.18 In rat CP 
epithelial cell culture experiments, TTR was found to sequester Aβ in the CSF and 
guided Aβ to the CP for enzymatic degradation and removal.19, 20 TTR is suggested as 
a protease with apolipoprotein A-I (apoA-I) and Aβ as substrates.21 TTR cleaves 
Aβ in multiple positions with some of the generated Aβ peptides displaying lower 
amyloidogenic potential than the full-length counterpart.18 As TTR was able to 
degrade aggregated forms of Aβ, it may contribute not only to the maintenance of Aβ 
levels within a normal range, but also to the removal of deposited Aβ in case of 
imbalance and disease.   
 TTR-Aβ interaction seems to have a neuroprotective effect in AD patients. 
TTR levels in the brains of AD patients are negatively correlated with the abundance 
of amyloid plaques,22 and TTR is upregulated in response to elevated Aβ levels in 
transgenic mice overexpessing mutant amyloid precursor protein.23 Significant 
reduction of TTR concentration in CSF of AD patients, compared to normal age 
controls was found by a number of studies,24–27 suggesting the AD patients either 
having reduced TTR production or depleting TTR with enhanced level of Aβ in the 
brain. While Schultz et al.28 did not find significant changes in TTR in CSF between 
AD patients and normal controls, but found a significant reduction in 
CSF TTR (14%) in AD patients who were medicated with cholinesterase inhibitors 
compared to those AD patients who were not. 
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This study was to characterize roles of TTR on β-amyloid clearance from CSF 
in comparison to thyroxine (T4) using an in situ mouse brain perfusion technique, and 
unravel mechanism of both T4 and Aβ efflux in a physiology model. 
 
2. RESULTS 
 
2.1. Baseline distribution of 125I-T4/125I-Aβ40 in the brain 
 
At baseline, levels of both 125I-T4 and 125I-Aβ40 in the brain were significantly higher than 
their size matched extracellular markers (mannitol and inulin), suggesting active uptakes of 
T4 and Aβ40 (Fig 1a, Fig 2a). Regionally, net levels of 125I-T4 and 125I-Aβ40 in the CP, EP, 
were higher than those in FX and CB, presumably the latter tissues were further away from 
the injection site – the lateral ventricles (Figs. 3,4).  
 
2.2. Efflux half time of 125I-T4 / 125I-Aβ40  
 
Levels of 125I-T4, 125I-Aβ40 as well as the extracellular makers fell over time in whole brain 
and in the CSF secreting CP (Figs. 1,2). These generated linear relation curves, by which the 
half time for efflux was calculated as in the Table 1. Table 1 showed the efflux half time of 
both 125I-T4 and 125I-Aβ40 were shorter than their size matched extracellular markers 
(mannitol and inulin), suggesting specific transporters for 125I-T4 and 125I-Aβ40. 
 
2.3. Effects of TTR on 125I-T4 / 125I-Aβ40 in the brain 
 
In the presence of TTR, levels of 125I-T4 fell over the time but at slower rates, leading to 
significant prolonged half time of 125I-T4 efflux in brain parenchyma (Fig. 1, Table 1). 
However, TTR did not significantly change the 125I-Aβ40 efflux half time in brain 
parenchyma (Fig. 2, Table 1). There was a noticeable increase in the uptake of 125I-T4 and 
125I-Aβ40 in the CP in presence of TTR compared to the baseline, whilst uptakes of 3H-
mannitol and 3H-inulin remained similar to control experiments (Fig. 3,4). TTR had no 
significant effect on the integrities of 125I-Aβ40, as the percentage of loss of 125I activity 
(cpm in supernatant) were almost equal in treatment groups (41.3 ± 4.5% and 42.7 ± 5% in 
TTR 50, 200 µg/mL respectively, versus 41.5 ± 6.3% in control group, P > 0.05). 
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3. DISCUSSION 
 
This study investigated the effect of TTR on T4 and amyloid efflux from the CSF. At 
baseline (without TTR), both 125I-T4 (775 Da) and 125I-Aβ40 (4455 Da) were cleared from 
brain faster than their corresponding extracellular markers, 3H-mannitol (182 Da) and 3H-
inulin (5000 Da), consistent with the concept of specific transporters for 125I-T4 and 125I-
Aβ40, in addition to the diffusion and fluid drainage pathways accessible by mannitol and 
inulin. With TTR in aCSF, the loss of thyroxin from the brain was significantly reduced (i.e. 
efflux half time was prolonged), while the retention of Aβ40 in the brain was not 
significantly affected (i.e. efflux half time was not changed). In presence of TTR, the 
accumulation of both 125I- T4 and 125I-Aβ40 in the CP were significantly increased. Since the 
nascent CSF is washed out from the ventricular system during perfusion with artificial CSF 
in the experiments, the CSF endogenous TTR approaches zero in these mice during the 
perfusion. 
TTR is a protein that binds and distributes the TH in the body. In the blood, >99% of 
TH is bound to specific plasma proteins known as TH distributor proteins, such as TBG, 
TTR, albumin and ApoB100.7 These TH binding proteins maintain the large extrathyroidal 
pool of TH which can be liberated with great rapidity for entry into cells, ensure a constant 
supply of TH to the cells and tissues.1, 7 In the CSF, TTR assumes the main role  in terms of 
TH homeostasis, as TTR has higher affinity to T4 than the albumin (~5–9 × 10–8 mol/L vs 
~7 × 10–5M).1 We showed here that TTR affected T4 distribution in the brain and prevented 
the T4 loss from the brain. The increased accumulation of T4 in the CP by TTR may be due 
to reduced basolateral efflux (from choroid epithelial cells to plasma) as well as an 
augmented uptake of T4 from CSF. The T4 efflux from the CSF involves a number of 
transporters29 and is saturable in presence of unlabelled T4.9, 11, 30 Despite the important role 
of TTR in TH homeostasis, mice lacking the TTR gene maintain normal functioning of 
thyroid glands in the face of significant reduction in total serum T4 concentration.9 Using the 
same model it was found that TTR was not essential for TH to reach the brain.8 This is not 
surprising given there are numerous mechanisms for T4 transport, and a number of thyroxine 
binding proteins may take over the role of TTR in TTR-null mice. Despite the apparent 
normal distribution of T4 in the brain, TTR knock-out mice have behavioural changes, which 
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are associated with an apparent increase of noradrenaline in the limbic forebrain of the 
mice.31, 32  
It has been suggested that TTR has other important physiological effects. TTR could 
bind Aβ and prevent amyloid formation, and also inhibit Aβ induced cytotoxicity.13, 14, 18  
Aβ deposition in the brain has been linked to the AD pathogenesis. The accumulation of Aβ 
in the AD brain is suggested to be related to defective Aβ clearance from the brain rather 
than increased Aβ production.33 P-gp and low-density lipoprotein receptor-related protein-1 
(LRP-1) in cerebrovasculature have been reported to play important roles in Aβ clearance 
from the brain to the blood.34 A recent study demonstrated that TTR interacted with Aβ 
directly and stimulated brain-to-blood but not blood-to-brain Aβ permeability in 
hCMEC/D3, a human cerebral microvascular endothelial cell line.35 Together with one of 
their previous studies,36 they conclude that TTR acts as an Aβ carrier that transports the 
peptide to its receptor both at blood brain barriers in the brain and at the liver in the 
peripheral system.35, 36 In the current study, we intended to use TTR concentrations close to 
the physiology level in mouse CSF (20–50 µg/mL),37 which are more than that of 125I –
Aβ40. The TTR dose effect was not seen. Thus, we could use one dose of TTR (i.e. 
50 µg/mL) in the study. That will be close to the clinical setting. At physiological condition 
in human, TTR is abundant (5–20 µg/mL or 0.1–0.36 µmol/L)38 while Aβ concentration in 
CSF is relatively low (3 nmol/L or less).39, 40 The effects of TTR on Aβ neurotoxicity have 
also been demonstrated in in vivo experiments. The silencing the endogenous TTR gene 
accelerated the appearance of Aβ associated neuropathology, while genetically programmed 
overexpression of a human TTR transgene suppressed both the neuropathologic and 
behavioural abnormalities in the APP23 transgenic mouse model.41 Backcrossing of the 
TTR null mice with an AD mouse model resulted in an increase in the deposition of Aβ in 
the brains of mice with the hemizygous deletion of TTR.42 TTR concentration in the CSF 
was found to negatively correlate with AD patients,43 as well as the degree of dementia in 
patients with AD.44 However, TTR was not found to change in AD patients compared to 
age-matched controls in a number of larger AD clinical studies such as ADNI (The 
Alzheimer's disease neuroimaging initiative).28, 45  
As the main tissue in the brain to secrete CSF and synthesize TTR, the CP is 
suggested to be a major site of Aβ removal in the brain. In a triple transgenic mouse model 
of AD, CP dysfunction was shown linking to increasing Aβ burden resulting in reduced 
production of CSF and diminished secretion of TTR.46 In AD patients, CSF 
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turnover/clearance is decreased by 50%.47 It will decrease Aβ40 clearance from the brain 
and increase the contact time for proteins with glucose in the CSF, which promotes the 
glycosylation of CSF proteins and increased oxidative stress.48 The CP also contains high 
levels of Aβ degrading enzymes, such as neprilysin, endothelin-converting enzyme-1, 
insulin degrading enzyme,19 which degrade β-amyloid peptides. In our study we showed 
TTR bound to Aβ40 and distributed Aβ40 to the CP, as the CP has high affinity to TTR due 
to presence of TTR receptor.49 We found significant loss of the integrity of 125I-Aβ / TTR 
complex in the brain tissue detected by the TCA precipitation assay. The loss of radioisotope 
activity in the precipitate could be due to involvement of enzymatic degradation in the CP, 
blood brain barrier or brain parenchyma. The accumulation / degradation of Aβ40 in the CP 
enhance Aβ40 removal which is known to occur at the CPs via receptor mediated processes 
(e.g. via the LRP1) that are modulated by chaperone complexes such as ApoE,  clusterin, 
TTR.50 In the CP, the abundance of LRP-1 increases with age, whereas the abundance of 
LRP-2 (megalin) is reduced during normal ageing in rodents.51 Megalin is thought to 
contribute to the clearance of Aβ through the CP,52 and patients with AD have reduced 
levels of megalin at the CP.53 Since the BBB is not intact with the clearance deficits in the 
AD patients, the role of Aβ transport and degradation at the CP becomes increasingly more 
prominent and needs further investigating.  
In conclusion, this study demonstrates that TTR acts differentially on T4 and Aβ40 
efflux from the CSF. TTR prevents the loss of thyroxine from the CSF, a positive adaptation 
since T4 is a substrate for multiple efflux transporters from the CSF, but is a necessary 
requirement for normal brain function. TTR does not significantly affect the retention of 
Aβ40 in the brain parenchyma, but redistributes Aβ40 to the CP for degradation and 
clearance. As a major site of TTR synthesis in the brain, the CP is an important site for 
homeostasis of TTR binding hormone and peptides.  
 
4. METHODS 
 
4.1. Mouse lateral ventricular perfusion 
 
All procedures were within the guidelines of the Animals (Scientific procedures) Act, 
UK, 1986. Eight-week-old C57/BL6 male mice (20–25 g) were ordered from Harlan 
(Huntington, UK) and were kept on a 12-hour light/dark cycle with food and water 
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freely available. They were anaesthetized with i.p. 0.1 mL Vetalar (100 mg/mL 
ketamine anaesthetic) and 0.2 mL Domitor (1 mg/mL medetomidine 
analgesic/sedative) and injected with heparin (1000 U/kg). The mice were put on a 
stereotaxic frame, the scalp removed and a hole made in the skull above each lateral 
ventricle, 1.0 mm lateral and 1.0 mm posterior to the bregma. A 33 gauge needle was 
used to make the hole, and had a tubing guard which kept the depth of the holes 
constant (2.5 mm).   
 
A syringe driver contained artificial CSF (aCSF) (all g/L: NaCl, 6.821; KCl, 0.2238; 
MgCl2 6H2O, 0.1626; Na2HPO4, 0.0994; NaHCO3, 1.512; Urea, 0.1202; Glucose, 
2.178; CaCl24H2O, 0.2058) with either 125I-T4 (0.037 MBq/mL; 8.62 nmol/L) plus 
3H-mannitol (0.148 MBq/mL; 26.47 µmol/L) or 125I-Aβ40 (0.09 MBq/mL; 1.1 n 
mol/L) plus 3H inulin (0.37 MBq/mL; 15.4 µ mol/L) was run at 1µl.min-1 for 1 min at 
either absence or presence of TTR (50 or 200 µg/mL). Aβ40 was studied in this 
study, as it is several folds higher than Aβ42 in the brain and its accumulation 
disrupts the integrity of BBB,54 although Aβ40 is less pathogenic than Aβ42 due to 
its low propensity to aggregate.55 The radio-labelled mannitol (182 Da) and inulin 
(5000 Da) acted as size-matched, non-transported, extracellular markers for 125I-T4 
(775 Da) and 125I-Aβ40 (4455 Da) respectively. Radio-isotopes were purchased from 
GE Life Sciences (Little Chalfont, England) and Perkin-Elmer (Boston, MA, USA).  
Human TTR (huTTR) was obtained from Biodesign International (Saco, ME, 
USA) and dissolved in saline. 100 µL of either 125I-T4 (0.037 MBq/mL; 8.62 n mol/L) 
or 125I-Aβ40 (0.09 MBq/mL; 1.1 nmol/L) was mixed with 1 mL of TTR 
(50/200 µg/mL; 0.909/3.636 µmol/L). The mixture was allowed to bind for 30 
minutes at room temperature and was then dialyzed overnight at 4 °C in seamless 
cellulose tubing (with a cutoff of 12 kD mol wet) (Sigma, St. Louis, MO, USA) to 
remove any unbound T4 or Aβ40.  
 
4.2. Sampling of the brain tissue, TCA precipitation and radioactive counting 
 
At 2, 4, 8, 16, 24 minutes after the injection, the mice were killed with an overdose 
sodium pentobarbital. The heart was exposed and blood taken using a syringe inserted 
in the left ventricle. The brain was then washed with cold phosphate buffered saline 
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(PBS) and was dissected into right and left frontal cortex (FX), choroid plexus (CP), 
ependymal lining lateral ventricles (EP), hippocampus (HC), cerebellum (CB) and 
rest of brain (ROB). Samples were weighed on a Cahn microbalance 
(ThermoScientific, Waltham, MA, USA), and homogenized with PBS in a glass 
homogenizer. 
The TCA precipitation method was used to determine how much 125I was still 
attached to Aβ at the end of the experiments.56 To measure intact 125I-Aβ, one volume 
of TCA (20%) was added to the sample, and then samples were vortexed, incubated 
in ice for 30 minutes and centrifuged at 14,000 rpm at 4 °C for 30 minutes. Following 
centrifugation, radioactivity of precipitated 125I-Aβ40 (intact peptide) and TCA 
supernatant (degraded peptide) were measured on a LKB Rackbeta liquid scintillation 
counter (Wallac, Turku, Finland). Solvables (National Diagnostics, Yorkshire, UK) 
was added to each of samples to dissolve organic samples overnight. The 
radioactivities of the tissues and 100 μL of infused aCSF were determined by liquid 
scintillation counting (LKB Wallac Rackbeta Spectral 1219 counter) after the 
addition of 3.0 mL liquid scintillation fluid (Ultima Gold, Packard Bioscience, 
Groningen, the Netherlands).   
 
4.3. Expression of results 
Regional brain uptake (volume of distribution) was calculated using the equation: 
 
Vd (mL/g) = 100 × (Tissue dpm/g) / (aCSF dpm/mL)    (1) 
 
The half-time for efflux of 125I-T4 and 125I-Aβ40 from brain was calculated according 
to Banks et al [57]. Briefly, LogVd was plotted against time and the slope of the line 
was calculated where: 
 
Efflux half time (minutes) = Log2 / slope of line     (2) 
  
4.4. Data analysis 
All values are expressed as mean ± standard error of the mean (SEM). ANOVA and 
unpaired t-test as appropriate were used to compare means. Values of P < 0.05 were 
considered statistically significant. 
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FIGURE 1    125I-T4 efflux after lateral ventricle injection. Levels of 125I-T4 and its size 
matched extracellular marker 3H-mannitol fell over time in whole brain. (a) 125I-T4 was 
cleared faster than 3H-mannitol at the baseline. The addition of TTR (b) 50 µg/mL; (c) 
200 µg/mL) slowed the 125I-T4 clearance but did not affected 3H mannitol one. Solid squares 
are 125I-T4 LogVd while open squares represent 3H-mannitol LogVd. Values are mean ± 
SEM, n = 3–5. 
 
FIGURE 2    125I-Aβ40 efflux after lateral ventricle injection. Levels of 125I-Aβ40 and its 
size matched extracellular marker 3H-inulin fell over time in whole brain. (a) 125I-Aβ40 was 
cleared faster than 3H-inulin at the baseline. The addition of TTR (b) 50 µg/mL; (c) 
200 µg/mL) did not affect the 125I-Aβ40 and 3H-inulin clearance (b, c). Solid circles are 125I-
Aβ40 LogVd, while open circles represent 3H-inulin LogVd. Values are mean ± SEM, n=3–
5. 
 
FIGURE 3    Regional brain uptake of 125I-T4 at 16 minutes post lateral ventricle injection. 
Baseline uptake of 125I-T4 showed highest accumulation in the CP (choroid plexus). The 
ependymal ventricular lining (EP) also showed some uptake of 125I-T4, however, the rest of 
the brain did not show much uptake. The addition of TTR to the lateral ventricles resulted in 
increased retention of 125I-T4 in the CP, and the increase reached significance with TTR 200 
µg/mL. The addition of TTR did not change retention of 125I-T4 in EP, HC, FX and CB. HC, 
hippocampus; FX, front cortex; CB, cerebellum. Values are mean ± SEM, n=3–5. *means 
P < 0.05 compared to baseline. 
 
FIGURE 4    Regional brain uptake of 125I-Aβ40 at 16 minutes post lateral ventricle 
injection. Baseline uptake of 125I-Aβ40 showed highest accumulation in the CP (choroid 
plexus). Brain parenchymal uptake was lower, and only the ependymal ventricular lining 
(EP) showed some uptake of 125I-Aβ40. The addition of TTR to the lateral ventricles 
resulted in significant increased retention of 125I-Aβ40 in the CP, but did not change 
retention of 125I -Aβ40 in EP, HC, FX and CB. HC, hippocampus; FX, front cortex; CB, 
cerebellum. Values are mean ± SEM, n = 3–5. * means P < 0.05 compared to baseline. 
 
